The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies

Cynthia Gyamfi; Amanda L. Horton; Valerija Momirova; Dwight J. Rouse; Steve N. Caritis; Alan M. Peaceman; Anthony Sciscione; Paul J. Meis; Catherine Y. Spong; Mitchell Dombrowski; Baha Sibai; Michael W. Varner; Jay D. Iams; Brian M. Mercer; Marshall W. Carpenter; Julie Lo; Susan M. Ramin; Mary Jo O'Sullivan; Menachem Miodovnik; Deborah Conway

doi:10.1016/j.ajog.2009.06.036

The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies

Cynthia Gyamfi, Amanda L. Horton, Valerija Momirova, Dwight J. Rouse, Steve N. Caritis, Alan M. Peaceman, Anthony Sciscione, Paul J. Meis, Catherine Y. Spong, Mitchell Dombrowski, Baha Sibai, Michael W. Varner, Jay D. Iams, Brian M. Mercer, Marshall W. Carpenter, Julie Lo, Susan M. Ramin, Mary Jo O'Sullivan, Menachem Miodovnik, Deborah Conway

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Abstract

Objective: To compare the rates of gestational diabetes among women who received serial doses of 17-alpha hydroxyprogesterone caproate vs placebo. Study Design: Secondary analysis of 2 double-blind randomized placebo-controlled trials of 17-alpha hydroxyprogesterone caproate given to women at risk for preterm delivery. The incidence of gestational diabetes was compared between women who received 17-alpha hydroxyprogesterone caproate or placebo. Results: We included 1094 women; 441 had singleton and 653 had twin gestations. Combining the 2 studies, 616 received 17-alpha hydroxyprogesterone caproate and 478 received placebo. Among singleton and twin pregnancies, rates of gestational diabetes were similar in women receiving 17-alpha hydroxyprogesterone caproate vs placebo (5.8% vs 4.7%; P = .64 and 7.4% vs 7.6%; P = .94, respectively). In the multivariable model, progesterone was not associated with gestational diabetes (adjusted odds ratio, 1.04; 95% confidence interval, 0.62-1.73). Conclusion: Weekly administration of 17-alpha hydroxyprogesterone caproate is not associated with higher rates of gestational diabetes in either singleton or twin pregnancies.

Original language	English (US)
Pages (from-to)	392.e1-392.e5
Journal	American Journal of Obstetrics and Gynecology
Volume	201
Issue number	4
DOIs	https://doi.org/10.1016/j.ajog.2009.06.036
State	Published - Oct 2009
Externally published	Yes

Keywords

17-α hydroxy progesterone caproate
gestational diabetes
singletons
twins

ASJC Scopus subject areas

Obstetrics and Gynecology

Access to Document

10.1016/j.ajog.2009.06.036

Cite this

Gyamfi, C., Horton, A. L., Momirova, V., Rouse, D. J., Caritis, S. N., Peaceman, A. M., Sciscione, A., Meis, P. J., Spong, C. Y., Dombrowski, M., Sibai, B., Varner, M. W., Iams, J. D., Mercer, B. M., Carpenter, M. W., Lo, J., Ramin, S. M., O'Sullivan, M. J., Miodovnik, M., & Conway, D. (2009). The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology, 201(4), 392.e1-392.e5. https://doi.org/10.1016/j.ajog.2009.06.036

Gyamfi, C, Horton, AL, Momirova, V, Rouse, DJ, Caritis, SN, Peaceman, AM, Sciscione, A, Meis, PJ, Spong, CY, Dombrowski, M, Sibai, B, Varner, MW, Iams, JD, Mercer, BM, Carpenter, MW, Lo, J, Ramin, SM, O'Sullivan, MJ, Miodovnik, M & Conway, D 2009, 'The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies', American Journal of Obstetrics and Gynecology, vol. 201, no. 4, pp. 392.e1-392.e5. https://doi.org/10.1016/j.ajog.2009.06.036

@article{784e76e9fbfd4815a4f2bb514d085134,

title = "The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies",

abstract = "Objective: To compare the rates of gestational diabetes among women who received serial doses of 17-alpha hydroxyprogesterone caproate vs placebo. Study Design: Secondary analysis of 2 double-blind randomized placebo-controlled trials of 17-alpha hydroxyprogesterone caproate given to women at risk for preterm delivery. The incidence of gestational diabetes was compared between women who received 17-alpha hydroxyprogesterone caproate or placebo. Results: We included 1094 women; 441 had singleton and 653 had twin gestations. Combining the 2 studies, 616 received 17-alpha hydroxyprogesterone caproate and 478 received placebo. Among singleton and twin pregnancies, rates of gestational diabetes were similar in women receiving 17-alpha hydroxyprogesterone caproate vs placebo (5.8% vs 4.7%; P = .64 and 7.4% vs 7.6%; P = .94, respectively). In the multivariable model, progesterone was not associated with gestational diabetes (adjusted odds ratio, 1.04; 95% confidence interval, 0.62-1.73). Conclusion: Weekly administration of 17-alpha hydroxyprogesterone caproate is not associated with higher rates of gestational diabetes in either singleton or twin pregnancies.",

keywords = "17-α hydroxy progesterone caproate, gestational diabetes, singletons, twins",

author = "Cynthia Gyamfi and Horton, {Amanda L.} and Valerija Momirova and Rouse, {Dwight J.} and Caritis, {Steve N.} and Peaceman, {Alan M.} and Anthony Sciscione and Meis, {Paul J.} and Spong, {Catherine Y.} and Mitchell Dombrowski and Baha Sibai and Varner, {Michael W.} and Iams, {Jay D.} and Mercer, {Brian M.} and Carpenter, {Marshall W.} and Julie Lo and Ramin, {Susan M.} and O'Sullivan, {Mary Jo} and Menachem Miodovnik and Deborah Conway",

year = "2009",

month = oct,

doi = "10.1016/j.ajog.2009.06.036",

language = "English (US)",

volume = "201",

pages = "392.e1--392.e5",

journal = "American Journal of Obstetrics and Gynecology",

issn = "0002-9378",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies

AU - Gyamfi, Cynthia

AU - Horton, Amanda L.

AU - Momirova, Valerija

AU - Rouse, Dwight J.

AU - Caritis, Steve N.

AU - Peaceman, Alan M.

AU - Sciscione, Anthony

AU - Meis, Paul J.

AU - Spong, Catherine Y.

AU - Dombrowski, Mitchell

AU - Sibai, Baha

AU - Varner, Michael W.

AU - Iams, Jay D.

AU - Mercer, Brian M.

AU - Carpenter, Marshall W.

AU - Lo, Julie

AU - Ramin, Susan M.

AU - O'Sullivan, Mary Jo

AU - Miodovnik, Menachem

AU - Conway, Deborah

PY - 2009/10

Y1 - 2009/10

N2 - Objective: To compare the rates of gestational diabetes among women who received serial doses of 17-alpha hydroxyprogesterone caproate vs placebo. Study Design: Secondary analysis of 2 double-blind randomized placebo-controlled trials of 17-alpha hydroxyprogesterone caproate given to women at risk for preterm delivery. The incidence of gestational diabetes was compared between women who received 17-alpha hydroxyprogesterone caproate or placebo. Results: We included 1094 women; 441 had singleton and 653 had twin gestations. Combining the 2 studies, 616 received 17-alpha hydroxyprogesterone caproate and 478 received placebo. Among singleton and twin pregnancies, rates of gestational diabetes were similar in women receiving 17-alpha hydroxyprogesterone caproate vs placebo (5.8% vs 4.7%; P = .64 and 7.4% vs 7.6%; P = .94, respectively). In the multivariable model, progesterone was not associated with gestational diabetes (adjusted odds ratio, 1.04; 95% confidence interval, 0.62-1.73). Conclusion: Weekly administration of 17-alpha hydroxyprogesterone caproate is not associated with higher rates of gestational diabetes in either singleton or twin pregnancies.

AB - Objective: To compare the rates of gestational diabetes among women who received serial doses of 17-alpha hydroxyprogesterone caproate vs placebo. Study Design: Secondary analysis of 2 double-blind randomized placebo-controlled trials of 17-alpha hydroxyprogesterone caproate given to women at risk for preterm delivery. The incidence of gestational diabetes was compared between women who received 17-alpha hydroxyprogesterone caproate or placebo. Results: We included 1094 women; 441 had singleton and 653 had twin gestations. Combining the 2 studies, 616 received 17-alpha hydroxyprogesterone caproate and 478 received placebo. Among singleton and twin pregnancies, rates of gestational diabetes were similar in women receiving 17-alpha hydroxyprogesterone caproate vs placebo (5.8% vs 4.7%; P = .64 and 7.4% vs 7.6%; P = .94, respectively). In the multivariable model, progesterone was not associated with gestational diabetes (adjusted odds ratio, 1.04; 95% confidence interval, 0.62-1.73). Conclusion: Weekly administration of 17-alpha hydroxyprogesterone caproate is not associated with higher rates of gestational diabetes in either singleton or twin pregnancies.

KW - 17-α hydroxy progesterone caproate

KW - gestational diabetes

KW - singletons

KW - twins

UR - http://www.scopus.com/inward/record.url?scp=70349308198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349308198&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2009.06.036

DO - 10.1016/j.ajog.2009.06.036

M3 - Article

C2 - 19716543

AN - SCOPUS:70349308198

SN - 0002-9378

VL - 201

SP - 392.e1-392.e5

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

IS - 4

ER -

The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this